Page last updated: 2024-12-07

2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The chemical name you provided, **2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile**, is a very specific and complex organic molecule. It's highly unlikely to be a widely known or studied compound, and there's a chance it may not even exist.

Here's why:

* **No known compound:** There's no readily available information on a compound with that exact structure. It might be a synthetic compound specifically designed for a particular research project, or it might be a hypothetical structure.
* **Lack of common uses:** The structure suggests it could be a potential drug candidate or a synthetic intermediate for drug synthesis. However, without more context, it's impossible to say for sure.
* **Importance depends on context:** If this compound was specifically designed for research, its importance would depend on the research goals. For example, it could be a potential inhibitor for a specific enzyme or a building block for creating a new type of drug.

**To determine the importance of this compound, we need more information:**

* **Context:** Where did you encounter this name? Was it in a scientific publication, a research project, or somewhere else?
* **Purpose:** What was the intended use of the compound? Was it for research, synthesis, or something else?
* **Research goals:** What is the specific research question or goal related to this compound?

Without this additional information, it's impossible to assess the importance of 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile.

2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

D617 : A nitrile that is pentanenitrile substituted by a 3,4-dimethoxyphenyl group at position 2, a methylamino group at position 4 and an isopropyl group at position 2. It is a metabolite of the drug verapamil. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID93168
CHEMBL ID1743342
CHEBI ID83528
SCHEMBL ID6387741
MeSH IDM0461757

Synonyms (41)

Synonym
34245-14-2
2-(3,4-dimethoxyphenyl)-5-methylamino-2-isopropylvaleronitrile
FT-0665436
2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-propan-2-ylpentanenitrile
CHEMBL1743342 ,
chebi:83528 ,
2-(3,4-dimethoxyphenyl)-2-isopropyl-5-(methylamino)pentanenitrile
A822789
3-(3,4-dimethoxyphenyl)-2-methyl-6-methylaminohexane-3-carbonitrile
3,4-dimethoxy-alpha-(3-(methylamino)propyl)-alpha-(1-methylethyl)benzeneacetonitrile
einecs 251-895-1
2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile
unii-l49d7pr96d
l49d7pr96d ,
bdbm50418097
rac d 617 (verapamil metabolite)
2-(3,4-dimethoxyphenyl)-2-isopropyl-5-(methylamino)valeronitrile
n-methyl-4-(3,4-dimethoxyphenyl)-4-cyano-5-methylhexylamine
verapamil hydrochloride impurity f [ep impurity]
d-617, (rs)-
benzeneacetonitrile, 3,4-dimethoxy-.alpha.-(3-(methylamino)propyl)-.alpha.-(1-methylethyl)-
(2rs)-2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-(1-methylethyl)pentanenitrile
d-617
SCHEMBL6387741
2-(3',4'-dimethoxyphenyl)-2-isopropyl-5-methylamino pentanenitrile
2-(3',4'-dimethoxyphenyl)-2-isopropyl-5-methylaminopentanenitrile
4-cyano-4-(3,4-dimethoxyphenyl)-5,n-dimethyl-hexylamine
d617
2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-(propan-2-yl)pentanenitrile
benzeneacetonitrile, 3,4-dimethoxy-.alpha.-[3-(methylamino)propyl]-.alpha.-(1-methylethyl)-
5-methylamino-2-(3,4-dimethoxyphenyl-2-isopropylvaleronitrile
2-(3,4-dimethoxyphenyl)-2-isopropyl-5-(methylamino)pentanenitrile #
rac d 617 (n-methyl-4-(3,4-dimethoxyphenyl)-4-cyano-5-methylhexylamine)
AKOS030255337
J-019519
verapamil metabolite d-617
Q27156918
3,4-dimethoxy-alpha-[3-(methylamino)propyl]-alpha-(1-methylethyl)benzeneacetonitrile;1-isopropyl-1-n-methylpropylamino-(3,4-dimethoxyphenyl)acetonitrile
DTXSID40891459
verapamil metabolite d617
SB82210

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The extent of verapamil bioavailability was directly measured in one patient receiving an intravenous dose as well as an oral one and was found to be 42."( Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
Metelitsa, VI; Nikolenko, SA; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO, 1986
)
0.27
" Following a dose of the slow-release preparation, the drug concentration curves were smoother and the mean bioavailability was lower in comparison with the conventional preparation."( Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
Barbieri, E; Cargnelli, G; Ferrari, M; Padrini, R; Piovan, D; Toffoli, M; Trevi, G, 1985
)
0.27

Dosage Studied

ExcerptRelevanceReference
"This study investigated the effect of verapamil metabolites on R- and S-verapamil protein binding in plasma samples collected from subjects prior to rac-verapamil dosing and following single dose and steady state rac-verapamil dosing."( Influence of metabolites on protein binding of verapamil enantiomers.
Akers, WS; Johnson, JA, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Verapamil Pathway, Pharmacokinetics76

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Ki7.93000.00011.41629.9000AID589141
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID589141Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID679127TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2000The Journal of pharmacology and experimental therapeutics, May, Volume: 293, Issue:2
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's5 (38.46)18.2507
2000's4 (30.77)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]